Lowest Price Guaranteed
Slides
247
Last Updated
July 2026
View Count
12031
The antimicrobial resistance surveillance market is valued at USD 6.64 billion in 2025 and is estimated to reach USD 11.32 billion by 2035, representing a higher CAGR of 5.47% during the forecast period.
To learn more about this report, request a free sample copy
Antimicrobial resistance surveillance is a collective measure used to monitor the pattern and prevalence of antimicrobial resistance across different microbial population. The primary aim of performing antimicrobial resistance surveillance is to track the spread and emergence of drug-resistance pathogens across the globe. With continuous usage of antibiotics for treating infectious diseases, microorganisms are developing mechanism to resist the therapeutic effects of live-saving drugs. In fact, antimicrobial resistance has become a major concern for healthcare experts as it creates challenges in the treatment of patients. As per the report of Centers for Disease Control and Prevention, over 2.8 million antimicrobial-resistance infections occur annually in the US. Moreover, the World Health Organization also indicated that antimicrobial resistance is one of the leading global public health threats.
With the continuous rise in the threat of antimicrobial resistant infections, numerous potential challenges are created for the treatment of patients. Thus, to overcome the growing incidence of antimicrobial resistance, several industrial leaders have boosted antimicrobial resistance surveillance. Under this surveillance, researchers collect data from antimicrobial susceptibility testing that are conducted on different samples, such as respiratory secretion, urine, blood and wound swabs. It is important to highlight here that several industry players are leveraging advanced molecular diagnostic techniques, such as real time PCR technology, microarrays, mass spectrophotometry, nucleic acid amplification test (NAAT) and genome sequencing (including next generation sequencing) to understand the mechanism of antimicrobial resistance.
Furthermore, the leading pharmaceutical companies are aiming to integrate artificial intelligence and organ-on-a-chip models to determine the underlying causes of antimicrobial resistance. The data collected from these innovative technologies has been used for designing personalized treatment plan for patients suffering from antimicrobial resistance.
In order to make antimicrobial surveillance programs more effective and assessable, the leading industry players are focusing on the development of diagnostic kits and diagnostic software for real time analysis. Furthermore, several players are actively undertaking initiatives, such as collaborations, acquisition, and partnerships to develop innovative diagnostics solutions. In June 2024, Sysmex announced the receival of Longitude Prize on AMR by Sysmex Astrego, for its PA-100 AST system (antimicrobial susceptibility testing system) that utilize nanofluidic technology for the detection. It is worth noting that the system is easy to use and provide results within 30 minutes, so as to support the healthcare professionals in designing the treatment plan effectively.
Furthermore, pharmaceutical companies are receiving constant support from industry and non-industry organizations to mitigate the growing concern of antimicrobial resistance. Given the ongoing efforts of leading players, and strategic initiatives, the global antimicrobial resistance surveillance market will continue to expand at a steady pace during the forecast period.
The market research report presents an in-depth analysis of various industry players that are involved in the global antimicrobial resistance surveillance industry, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2035 | $ 11.32 billion | |
| CAGR | 5.47% | |
| Type of Solution |
|
|
| Application |
|
|
| End User |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of antimicrobial resistance surveillance market report was to estimate the current market size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
The antimicrobial resistance surveillance market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as distribution by type of solution (diagnostic kits, diagnostic systems, diagnostic software and diagnostic services), application (clinical diagnostics, public health surveillance and other applications), end user (hospitals & clinics, research & academic institutes and other end users), geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on the type of solution, the global market is segmented into diagnostic kits, diagnostic systems, diagnostic software and service. According to our projection, currently diagnostic kits occupy the highest antimicrobial resistance surveillance market share (over 45%). Diagnostic kits (such as point-of-care testing kits) offer reliable results within minutes. This rapid detection has played a significant role in taking treatment decisions with a tailored approach for patients suffering with antimicrobial resistant infections. Furthermore, these diagnostics kits are user-friendly and have been designed to operate with minimal training, making it a valuable testing solution for healthcare professionals.
In addition, diagnostics kits have received regulatory support from the government and the USFDA, which further contributed to the highest share of diagnostics kits. However, with growing technological innovations and emphasizing telemedicine, diagnostic software will show lucrative growth potential and is expected to grow at a higher CAGR during the forecast period.
This segment highlights the distribution of global antimicrobial resistance surveillance market across various applications, such as clinical diagnostics, public health surveillance and other applications. Currently, clinical diagnostics accounts for the highest share (nearly 45%) of the market. This dominance is primary due to the fact that clinical diagnostics are directly involved in patient care. With increasing incidence of antimicrobial resistance, it is important to diagnose resistant pathogens at an early stage. Furthermore, the availability of advanced diagnostic solutions, software and skilled personnel in clinical diagnostics have contributed to the largest share of the clinical diagnostics.
It is important to highlight here that with increasing demand for advanced antimicrobial resistance solutions, this segment will continue to grow at a higher CAGR during the forecast period. Moreover, public health surveillance holds a significant share, supported by the growing investments and support from government organizations in antimicrobial resistance surveillance programs.
The global antimicrobial resistance surveillance market is categorized across different end users, such as hospitals & clinics, research & academic institutes and other end users. It is important to highlight here that hospitals & clinics hold the highest share (over 55%) of the overall market. Hospitals & clinics play an important role in monitoring and managing the pattern of antimicrobial resistance within patients. Furthermore, high patient pool and increased adherence to the standard guidelines to combat antimicrobial resistance, fostering the highest share of hospitals & clinics. Driven by the increasing efforts for the development of advanced therapeutics to overcome the issues of antimicrobial resistance, research & academic institutes will grow at a higher CAGR during the forecast period.
The global antimicrobial resistance surveillance market is distributed across various geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our projection, currently North America occupies the largest share (~45%) of the market. Several factors such as high incidence of antimicrobial resistance, advanced healthcare infrastructure, and support regulatory framework are contributing to the growth of this region. Furthermore, several established leaders, such as Abbott Laboratories and Roche are taking strategic initiatives for the development of rapid diagnostic kits and software that aids in determining antibiotic resistance in real time.
However, the market for antimicrobial surveillance in Asia-Pacific is likely to grow at a higher CAGR during the forecast period. This can be attributed to the fact growing government support and implementation of national antimicrobial resistance surveillance plans. In addition, the proactive approach such as collaborations between leading players for the development of diagnostic techniques has contributed to the growth of this region.
The“Antimicrobial Resistance Surveillance Market: Industry Trends and Global Forecast, till 2035” market report features a comprehensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities for the stakeholders.
The market landscape is highly competitive, featuring several industrial and non-industrial leaders. In order to mitigate the concern of antimicrobial resistance, industrial leaders are focusing on innovations and integration of data analytic tools / technologies that can critically address the antimicrobial resistance surveillance challenges. Furthermore, several industrial stakeholders are leveraging partnerships for the evolution of diagnostic technologies and software for faster recognition of antimicrobial resistance.
In addition, key organizations across the globe are active in this field and are expanding their surveillance programs to address the accelerated threat posed by the developing microbial resistance. For instance, in January 2024, the Union Health Ministry of India announced its plan to extend its antimicrobial resistance surveillance for drug resistant pathogens to nationwide secondary care hospital. Under this surveillance, the Indian Council of Medical Research will lead strategic initiatives for broadening antimicrobial resistance surveillance to smaller hospitals. With such government support and escalating efforts of industry players, we believe that the antimicrobial resistance surveillance market will remain competitive to offer lucrative opportunities for driving innovations.
The primary growth driver that will propel the market includes rising antimicrobial resistant infections and technological advances in diagnostic procedures. It is worth noting here that the development of multi-drug-resistant tuberculosis and other bacteria has heightened the demand for advanced surveillance initiatives to track resistance patterns. According to WHO, there were ~410,000 reported cases of multidrug-resistant TB in 2022.
Furthermore, the growing innovations and advancements in diagnostics technologies such as rapid multiplex assays, and point-of-care diagnostics for quick analysis has further accelerated growth of this market during the upcoming years. Additionally, the growing public-private partnerships between healthcare providers, governments and non-government organizations are encouraging to broaden antimicrobial resistance surveillance networks. These collaborations between several organizations and pharmaceutical companies for data sharing and designing treatment plans are contributing to the growth of this market.
At the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), a group of global leaders approved a political declaration, committing to reduce the estimated 4.95 million human deaths associated with bacterial antimicrobial resistance (AMR) annually by 10% by 2030. The surveillance systems will have to be strengthened in order to achieve these targets, driving the antimicrobial resistance surveillance market growth over the forecast period.
The market for antimicrobial resistance surveillance is experiencing several challenges that may hamper its growth during the forecast period. Some of the potential challenges include high cost, lack of data standardization and rapidly evolving resistance pattern. It is important to highlight that the involvement of advanced database technologies require transmission of data across different networks which poses risk of data threat. The lack of data standardization may result in inconsistent data collection which leads to a gap in determining the resistance patterns. Additionally, the implementation of state-of-the-art technologies may enhance the overall cost of implementing advanced diagnostic technologies.
Notably, the rapidly evolving resistance patterns among microbial strains may create challenges in designing advance drugs for treating patients. In order to overcome challenges, industry leaders need to emphasize data standardization protocol and integration of surveillance systems to enhance accuracy of antimicrobial resistance monitoring.
Some technological advancements in the market include integration of AI technology and global antimicrobial resistance and use surveillance system (GLASS). This integration of advanced surveillance system and AI technology ensures a standard approach to collect, analyze and share data across various channels to understand the pattern of antimicrobial resistance. Furthermore, the integration of advanced technology-based surveillance tools helps in the tracking of resistance outbreak, which further allows researchers to take a personalized approach for the development of treatment plans.
Additionally, the growing preferences for point-of-care testing solutions for on-site detection of developing antimicrobial resistance in diagnostic laboratories is offering an opportunity to develop more innovative solutions for rapid diagnostics. Furthermore, the generation sequencing technologies to identify resistant genes, mobile health applications and portable diagnostic technologies for remote monitoring are the key growth factors of the market.
The antimicrobial resistance surveillance market is currently valued at USD 6.64 billion and is estimated to reach USD 11.32 billion by 2035. According to a report published by UN Ad hoc Interagency Coordinating Group on Antimicrobial Resistance, AMR is anticipated to result in nearly 10 million deaths annually at the global level, by the year 2050. Also, presence of large number of antibiotic manufacturing factories in developing countries like India and China, and high usage of antibiotics will require these countries to step up their surveillance efforts. India is already a part of WHO’s GLASS, while China can benefit from the same by sharing data on national and global level. In order to address this growing concern, there has been a great demand for collective attempt by industry and non-industry players so as to support the healthcare industry to tackle this major concern.
In September 2024, Cepheid entered into a collaboration with Fleming Initiative (established by Imperial College Healthcare NHS Trust and Imperial College London) so as to explore the skills, expertise and knowledge to combat the AMR. As highlighted by Professor the Lord Darzi of Denham (Executive Chair, Fleming Initiative), “At the Fleming Initiative we aim to unlock powerful new ideas to drive significant change in the fight against AMR. This requires collective innovation across industries, from practitioners to policy-makers and the public. I am delighted to welcome Cepheid as our first diagnostics partner. Currently 20% of antibiotic prescriptions given in primary care lack an appropriate diagnosis. We have to do better. Cepheid's expertise will be essential to our efforts to ensure antibiotics work for generations to come."
Examples of key companies engaged in antimicrobial resistance surveillance industry (which have also been profiled in this market report; the complete list of leading players is available in the full report) include Abbott Laboratories, Accelerate Diagnostics, BD, bioMérieux, Bruker, Biospace, Cepheid, Danaher, Himedia Laboratories, Luminex, Merck, Opgen, Roche and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the protein engineering companies worldwide.
Several recent developments have taken place in the field of antimicrobial resistance surveillance. We have outlined some of these recent initiatives below.